Sign in
Taking peoplePhase 1

A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate

Key facts

Who runs it
Cinclus Pharma Holding AB
Where
Sweden1 site in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 1
People taking part
121 people, planned
Started
13 Jul 2022
Expected to end
30 Nov 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Linaprazan glurate
  • Placebo
Record updated
17 June 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 10 criteriaShow less

Other criteria

  • Main inclusion Criteria:
  • Willing and able to give written informed consent for participation in the study
  • Healthy male or female aged 18 to 65 years
  • Body mass index ≥18.5 and ≤35.0 kg/m2
  • Prospective subjects, as well as their partners, must agree to contraception requirements; Main exclusion criteria:
  • Female subjects of childbearing potential unless they agree to use highly effective methods of contraception (failure rate of <1%) from 2 weeks prior to dosing until the end-of-study visit
  • Male subjects with a partner of childbearing potential, unless they agree to use method of contraception from 2 weeks prior to dosing until the end-of-study visit.History of or current clinically significant disease as defined in the protocol
  • History of or current clinically significant disease as defined in the protocol
  • History of GERD, significant acid reflux
  • Subjects who are pregnant, currently breastfeeding, or intend to become pregnant (female subjects) or father a child (male subjects) during the course of the study (i.e., from screening to end of study visit)

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a Phase I, single-center, double blind, placebo-controlled, parallel-group, randomized trial designed to evaluate the PK, cardiodynamic ECG effects, safety, and tolerability of single oral doses of linaprazan glurate. The trial will explore the PK properties of linaprazan glurate and linaprazan as well as the cardiodynamic ECG effects, safety, and tolerability after the administration of single doses: 300 mg and 600 mg in Part I of the trial, using formulation A of linaprazan glurate, as well as 150 mg, 275 mg, and up to 2 additional dose levels, using formulation C of linaprazan glurate to reach target linaprazan mean Cmax exposure (5222 nmol/L).

The 2 groups in the trial

  • Linaprazan glurateTreatment being tested

    Oral administration as a single dose of 300 mg, 600 mg, 150 mg, 275 mg, and up to 2 additional dose levels.

  • PlaceboPlacebo, for comparison

    Oral administration as a singel dose

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase I Trial to Investigate the Pharmacokinetics and ECG Effects of Single Doses of Linaprazan Glurate Administered as Oral Tablets to Healthy Participants
Criteria questions
Built from NCT05469854, who can take part
Record updated
17 June 2026